Previous studies have shown that sera of patients with severe atopic dermatitis (AD) contain IgE specific for selfproteins, supporting the hypothesis of autoreactivity as a pathogenic factor in AD. In this study, we screened a large panel of AD patients (n ¼ 192) by western blotting (WB) for IgE reactivity not only against the human epithelial cell line A431 but also against primary keratinocytes (KCs). To investigate autoantigenic cell structures in detail, normal human skin and primary KCs were incubated with sera from both WB-reactive patients and, for control purposes, healthy individuals, and analyzed by immunohistology, confocal laser microscopy, and flow cytometry. Our analysis revealed that 28% of AD patients, but not healthy individuals, display serum IgE autoreactivity by WB analysis. The individual IgE reaction patterns of the sera pointed to the existence of unique as well as common specificities against epidermal or A431-derived proteins. Immunostainings identified cytoplasmic and, occasionally, also cell membrane-associated moieties as targets for autoreactive IgE antibodies. Interestingly, in certain autoreactive patients, the surface-staining pattern was accentuated at cellular contact sites. We conclude that IgE autoreactivity is common, particularly among severe AD patients, and that nontransformed primary cells are needed for characterization of the entire spectrum of IgE-defined autoantigens.
INTRODUCTION
Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease occurring in 5-20% of children and 1-3% of adults. Allergen studies indicate that approximately 80% of AD patients have elevated levels of total and exoallergenspecific IgE, which is directly associated with the severity of disease (Tan et al., 1996) . Moreover, there exists a small proportion of patients with the typical signs of AD in which sensitization to a broad panel of exoallergens is not detectable by in vitro or in vivo tests (Schmid-Grendelmeier et al., 2001) . This finding supports the involvement of either a non-immunological or an autoreactive pathomechanism in the perpetuation of the clinical manifestations.
In fact, in the past decade autoreactive IgE antibodies against self-proteins have been identified in AD (Valenta et al., 1996; Natter et al., 1998; Fluckiger et al., 2002) . Studies concerning endogenous antigens as triggers in AD have shown that sera from atopic patients, particularly those from patients with severe AD, contain IgE antibodies against human proteins expressed in histogenetically different cell types, most importantly in epithelial cells (Valenta et al., 1996; Natter et al., 1998; Seiberler et al., 1999a, b) . Some of the IgE-defined epithelial autoantigens (for example, Hom s 1-5) have been identified and characterized at the molecular level (Mossabeb et al., 2002) . These autoantigens are intracellular, mostly cytoplasmic proteins , suggesting that their release from damaged tissue would trigger responses mediated by IgE or T cells (Valenta et al., 1998) in AD patients.
Recombinant human autoallergens characterized so far result from immunoscreenings of an epithelial carcinoma cell line (A431) (Seiberler et al., 1999a, b) , which may not perfectly reflect the physiological repertoire of proteins expressed in the epidermis. Skin-derived autoantigens potentially relevant for the disease could thus have been overlooked. Therefore, we wanted to analyze the range of IgE autoreactivities against primary epidermal cell-derived proteins and to compare them with those against A431-derived proteins. Furthermore, we wished to discover against which cell type, subcellular structure, or non-cellular formations of the skin the IgE-autoantibodies were directed. By doing so, we sought to build a basis for future investigations of their molecular nature.
RESULTS

Serum IgE autoreactivity is present in one fourth of AD patients
In a first set of experiments, we analyzed the prevalence of epithelial cell-reactive serum IgE autoantibodies in a large study population of AD patients. A total of 192 patient sera were screened by western blotting (WB) with protein extracts derived from the epithelial cell line A431 and with epidermal extracts from the skin of one healthy donor. A serum was considered ''autoreactive'' if the IgE contained in it recognized at least one band in one of the protein extracts used. Healthy individuals completely lacked serum IgE reactivity against the above-mentioned protein extracts, whereas approximately one-fourth (28%, n ¼ 54) of all AD patients exhibited IgE reactivity against both epithelial extracts ( Figure 1 ). IgE autoreactivity against proteins derived from normal dermis was absent in all tested sera (data not shown), probably due to the cellular paucity of this tissue. IgE autoreactivity against primary epidermal extracts was irrespective of the healthy skin donor, indicating ubiquitous occurrence of autoantigens in healthy human skin. ( Figure S1 ).
IgE autoreactivity against epidermis-derived proteins is clearly associated with elevated total serum IgE and the severity of disease Next, we set out to identify common clinical features of autoreactive AD patients. Statistical analysis of the clinical data revealed that autoreactive AD patients exhibit significantly (Po0.001) higher total serum IgE levels when compared with non-autoreactive AD patients. Despite this significant correlation between IgE autoreactivity and high total serum IgE levels (41,000 IU ml À1 ), there also existed several AD patients with elevated serum IgE levels (o1,000 IU ml À1 ) who did not show autoreactivity against epithelial proteins. These patients provide an internal control and indicate that IgE autoreactivity does not occur as a nonspecific phenomenon due to high IgE levels.
Disease activity, as determined by the Investigators' Global Assessment (IGA) Score and the Eczema Area and Severity Index (EASI), was also significantly (Po0.001) higher in autoreactive patients than in non-autoreactive ones ( Figure 2 ). These data are in agreement with earlier observations showing that AD patients with serum IgE autoreactivity form a distinct subpopulation of patients with severe disease and considerably higher total serum IgE . In contrast to this observation, we were not able to find a significant correlation within the group of autoreactive AD patients between the intensity of the WB reaction or a special recognized moiety on the one hand and the EASI and IGA on the other (data not shown), indicating that IgE autoreactivity is an important but not the only relevant factor in this complex skin disease.
Interestingly, all of the IgE-autoreactive patients met the criteria of the extrinsic-type AD (that is, increased serum IgE and/or sensitization to environmental allergens; Wollenberg et al., 2000) , whereas in the group of the non-autoreactive AD patients 17% had a characteristic intrinsic-type AD (Schmid-Grendelmeier et al., 2001; Novak and Bieber, 2003) .
Comparison of the reactivity against epidermal protein extracts and A431 extracts
To investigate which protein extract is best suited for the detection of autoreactivity in AD patients, we compared reactivity against A431 with that against proteins extracted from freshly isolated keratinocytes (KCs) by WB. Of the 54 patients with IgE autoantibodies, 45 ( ¼ 83%) recognized primary epidermis-derived proteins and 42 ( ¼ 78%) recognized A431-derived proteins. Although most AD sera (61%) reacted with antigens in both the extracts (Table 1) , 12 AD patients ( ¼ 22%) reacted exclusively with extracts from epidermal tissue and nine ( ¼ 17%) exclusively with A431 extracts. These data indicate that potentially autoreactive patients could have been overlooked if the screening was solely performed with protein extracts derived from the cell line A431 and that a maximum detection can be achieved by 30 kDa 45 kDa 69 kDa 97 kDa
Healthy controls AD patients (Table 1) .
A detailed analysis of the band pattern in the western blots revealed that the IgE-autoreactive moieties in epidermal extracts differed in their molecular weights from those identified in A431 extracts by the very same sera. When analyzing interindividual serum reactivity against cell line A431, we could not detect prevalently recognized moieties among autoreactive AD patients. In contrast, when using primary epidermal extracts as an antigenic source, we were able to identify a common band of approximately 30 kDa in 60% of all autoreactive AD patients ( Figure 1 ).
Autoantigens are expressed by KCs in the skin
Next, we sought to determine which cells of the skin express IgE-defined autoantigens. For this purpose, frozen sections of normal human skin were incubated with the sera of 15 autoreactive AD patients or five healthy controls. Serum IgE that bound to the sections was detected with an anti-IgE antibody. We found that six of 15 patients, but none of the healthy individuals, showed detectable IgE reactivity against normal human epidermis. Figure 3 shows representative examples of such reaction patterns. Similar to the results obtained by WB, we detected an interindividually heterogeneous IgE-binding pattern. For example, serum IgE of AD patient I showed predominantly nuclear labeling, whereas that from patient II was preferentially bound to membraneassociated structures. In total, two of the 15 AD patients had clearly detectable serum IgE reactivity against the cell periphery of KCs.
Next, primary undifferentiated KCs were incubated with sera of the six AD patients, which had shown epidermal IgE binding by immunohistology (IH), and sera of two healthy controls. Using immunofluorescence microscopy, we were able to confirm the results derived from IH and showed that serum IgE binding is most pronounced at sites of cellular contact in the two patients with IgE reactivity against membrane structures ( Figure 3 ). This indicates that junctional structures may be targets for autoreactive IgE of certain patients. Anti-IgE immunostainings of KCs incubated with sera from healthy persons gave no detectable signal.
Autoantigens can occur on various subcellular structures of KCs, including cell surface
To determine whether the serum IgE of our patients exhibiting peripheral staining by immunofluorescence binds to extracellular or intracellular membrane structures of KCs, we performed FACS analysis with viable KCs that were non-enzymatically detached and probed with autoreactive AD serum. Surface-bound IgE was detected with mouse antihuman IgE mAb and Alexa488-labeled goat anti-mouse IgG antibody (Ab). Using this method, we found serum IgE binding to detached viable primary KCs in three of 15 autoreactive AD patients ( Figure S2 ). This binding of the autoreactive IgE in the three AD sera was almost completely prevented when the KCs were trypsin-treated before incubation with patient sera (data not shown), demonstrating that freely accessible surface proteins are the targets of autoreactive serum IgE. Surface IgE binding was limited to epithelial cells, with a significant preferential binding to primary KCs, and could not be detected on other tumor or primary cell types (Table S1 ), suggesting the recognition of KC-specific autoantigens.
In a next step, we also performed immunostainings with autoreactive sera on primary KCs cultured on slides (Figure 4 ). By this method, we detected membrane labeling of the viable cells in five of 15 autoreactive AD patients. Compared with FACS analysis, two additional, but rather weak, KC surface-reactive AD patients were identified by immunofluorescence, possibly due to the higher sensitivity of the latter method.
DISCUSSION
Although serum IgE reactivity against human proteins had been reported to occur in AD sera some 10 years ago (Valenta et al., 1996) , our knowledge about the significance of this phenomenon is still incomplete. The recombinant human autoallergens characterized so far (Hom s 1-5) result from immunoscreenings of the epithelial carcinoma cell line A431 with sera of autoreactive AD patients . Results obtained previously show that IgE reactivity of AD sera against these structures is a rather infrequent event Valenta et al., 1998; Mossabeb et al., 2002; Aichberger et al., 2005) . As the phenomenon of serum IgE autoreactivity occurs in approximately a quarter of our study population, Hom s 1-5 are likely to represent only a small fraction of the target antigens recognized by autoreactive IgE, suggesting that important autoreactive targets still await identification.
To address this issue, we decided to use primary epidermal cell extracts as a screening tool for IgE autoreactivity and to compare the results with the previously used extracts derived from A431. Our screening revealed that a considerable portion of AD patients (28%) exhibit serum IgE autoreactivity against epidermal extracts and extracts from the epithelial cell line A431. This autoreactivity in AD patients was significantly correlated with the severity of the disease, defined by the amount of total serum IgE and the clinical scores on the EASI and IGA. This relationship suggests that IgE autoantibodies are the result of repetitive and severe injury of the skin. Thus, it is conceivable that environmental exoallergens initiate the acute phase of the allergic cutaneous disease (Valenta et al., 2000) and thereby destruction of KCs and release of autoantigens into the circulation. IgE autoimmunity may consequently contribute to chronicity of the disease even in the absence of environmental allergens. This hypothesis is supported by longitudinal studies showing that IgE responses to autoallergens occasionally increase during periods of disease exacerbation, and by the discovery that some environmental allergens share structural and functional similarities with human proteins (Crameri et al., 1996; Meyer et al., 1999; Kinaciyan et al., 2002) .
Interestingly, all the autoreactive AD patients were of the extrinsic type (total serum IgE 4100 IU ml À1 and/or sensitization against common allergens). Three autoreactive patients displayed elevated total serum IgE but no sensitization against common allergens. These patients may be sensitized to exoallergens not tested by us, or, alternatively, the elevated total serum IgE may result from a ''pure'' reactivity against autoallergens. The latter explanation is in accordance with a report of two intrinsic-type AD patients with IgE autoimmunity against an exoallergen-crossreactive human protein (Schmid-Grendelmeier et al., 2005) .
An explanation for the significant correlation of autoreactivity and severity of the disease is that elevated autoreactive serum IgE levels themselves account for the worsening of disease. IgE immune complexes could target effector cells like mast cells and basophils (Valenta et al., 1996; Natter et al., 1998) , initiating the release of preformed mediators (that is, histamine, proteoglycans, tryptase, chymase), the production of cytokines (that is, IL-4, IL-5, IL-13), and, consequently, an allergic tissue response (Irani et al., 1989) . Support for this idea comes from the finding that purified recombinant IgE autoantigens caused histamine release from basophils and induced immediate type-I skin reactions (Valenta et al., 1991 (Valenta et al., , 1996 Crameri et al., 1996; Natter et al., 1998; Appenzeller et al., 1999) .
When we compared the moieties recognized in epidermal extracts and extracts derived from A431, we found incoherent band patterns in most autoreactive patients, indicating the presence of distinct autoantigens in the two protein extracts. Based on these results, we propose that extracts of freshly isolated skin cells reflect the in vivo antigen situation better than the A431 tumor cell extracts, and are thus indispensable for screening for autoreactive AD patients. In addition, a substantial proportion of autoreactive AD patients showed serum IgE reactivity selectively against proteins derived from epidermal and not A431 extracts, suggesting that autoreactive AD patients might have been overlooked when the screening was performed solely with cell line A431. We cannot definitely rule out the possibility that exogenous microbial antigens or allergens deposited in the skin are also recognized by serum IgE (Crameri et al., 1996; Schmid-Grendelmeier et al., 2005) . The fact that we detected IgE serum reactivity against several sterile epidermal cell line preparations (A431, HeLa) and normal epidermal extracts strongly suggests that IgE autoreactivity is a major component of the IgE self-reactivity observed.
The comparative analysis of the moieties recognized revealed that every patient's serum IgE was directed against an individual, very diverse spectrum of proteins in the respective extracts. This diverse reaction pattern may explain the low prevalence of serum IgE reactivity against the known autoantigens (Hom s). Interestingly enough, and unlike the situation with A431 extracts, we were able to identify a presumably commonly recognized moiety at around 30 kDa in extracts derived from epidermal sheets. Such a common target protein is of great interest, as more ubiquitous proteins are needed to analyze the pathogenetic relevance of these IgE-defined autoantigens.
To determine against which structures of the skin the serum IgE antibodies of the autoreactive patients are directed, we performed IH stainings of normal human skin sections that had been incubated with autoreactive serum IgE of AD patients. We found an individually variable staining pattern reaching from a predominant nuclear labeling throughout the whole epidermis to a specific labeling of the membranes of the basal layer cells. Flow cytometry and cytological analysis of viable cultured KCs revealed that the latter results from the staining of KC surfaces. Thus, the reported intracellular localization of autoantigens in AD (Crameri et al., 1996; Valenta et al., 1998; Fluckiger et al., 2002) is not an obligatory feature. Moreover, cytological analysis of cultured KCs revealed diverse forms of surface reactivity, indicating the existence of a variety of surface-reactive target molecules for IgE in the individual patients. It is particularly tempting to speculate that recognition of surface structures on KCs by serum IgE could result in a direct crosstalk between IgE and epidermal KCs, leading to perturbation and functional modulation of KC, similar to what has been described for IgG autoantibodies in diseases such as pemphigus vulgaris. In AD it is thus conceivable that autoreactive IgE antibodies are directly responsible for epidermal spongiosis.
It is also conceivable that KC surface-bound IgE facilitates contact formation with FceRI þ positive cells, such as LCs or IDECs (Stary et al., 2005) . This direct interaction may lead to enhanced antigen transfer from KCs to antigen-presenting cells, and, as a consequence, to IgE-facilitated autoantigen presentation Stary et al., 2005) , which may contribute to the chronicity of the disease (Mittermann et al., 2004) .
The frequent occurrence of IgE autoimmunity and its strong correlation with severity of the disease suggests a pathophysiologically important role of these autoantibodies in AD, although we cannot definitively exclude the possibility that they occur as a ''bystander'' phenomenon (Mittermann et al., 2004) . However, approximately a quarter of the AD patients exhibit serum IgE autoreactivity and the detection of autoreactive serum IgE is a useful serological marker for the disease activity in these patients. It defines a new subgroup of AD patients who may benefit from a treatment with an anti-IgE mAb (Lane et al., 2006) and, perhaps, from a specific immunotherapy. In this context, it also seems imperative to subject such individuals to effective antipruritic therapy, thus interrupting the vicious circle of scratching, release of autoantigen, and, ultimately, development of acute eczematous lesions. Such an intervention should probably be implemented early in the patient's life (Mothes et al., 2005) .
MATERIALS AND METHODS
Patients
We collected sera from 192 AD patients who had been diagnosed according to the criteria of Hanifin and Rajka (1980) . All individuals were tested for their total serum IgE level and allergen-specific serum IgE to common inhalant allergens, including grass pollen, birch pollen, ragweed, house dust mites, cats, dogs, and molds (Immuno-CAP system; Pharmacia, Uppsala, Sweden). Additionally, they were scored on the IGA, the EASI, and other clinical instruments (Hanifin et al., 2001; Eichenfield et al., 2005) . Table S2 gives an overview of the age, sex, mean total serum IgE, mean IGA, and mean EASI of the patients tested. All patients ceased atopy-specific therapy, such as steroids, topical calcineurin inhibitors, and antihistamines, at least 2 weeks before enrollment. Sera of non-allergic volunteers (n ¼ 26), without allergic personal history, served as controls. Sera were stored at -20 1C until investigation.
Tissue specimens
Whole skin: frozen tissue sections from normal adult human skin were purchased from BioChain (Hayward, CA).
Epidermal sheets and dermis: normal adult human skin from nonatopic individuals was obtained ex vivo from reduction surgery and split-thickness samples were prepared with a manual dermatome. Epidermal sheets were separated from the dermis after 1-hour dispase (Becton Dickinson, Franklin Lakes, NJ) digestion of the basement membrane as described previously (Kriehuber et al., 2001) .
Cell lines
The human epithelial cell line A431 was obtained from the American Type Culture Collection (ATCC, Rockville, MD). Cells were grown in RPMI 1640 medium (Invitrogen, Carlsbad, CA) supplemented with 2 mM L-glutamine, 100 U ml À1 penicillin, 100 mg ml À1 streptomycin, and 10% fetal calf serum (heatinactivated) at 37 1C, under 5% CO 2 , in a humidified incubator.
Primary human foreskin KCs were purchased from PromoCell (Heidelberg, Germany) and grown in EpiLife medium (Cascade Biologics, Portland, OR) supplemented with 0.006 mM Ca 2 þ .
Western blot
Cultured cells (A431) and freshly isolated epidermal and dermal sheets were dissolved in 2 Â reducing Lämmli buffer (120 mM Tris pH 6.8, 4% SDS, 20% glycerol, 2.5% b-mercaptoethanol) by sonication on ice. The protein extracts were cleared by high-speed centrifugation, boiled for 5 minutes at 96 1C, and stored at -20 1C until use. WB was performed as described previously (Kriehuber et al., 2001) . Briefly, proteins were separated by 12% SDS-PAGE, transferred by semi-dry electroblotting onto nitrocellulose membranes (0.2 mm; Biorad, Hercules, CA), and blocked with 5% dry milk (blocking grade; Biorad)/phosphate-buffered saline (PBS). The blots were then incubated with serum (1:5 diluted in blocking milk) at 4 1C for at least 12 hours and washed with PBS-T (PBS þ 0.1% Tween 20; Biorad). Binding of serum IgE was detected using the anti-human IgE mAb B3102E8 (horseradish peroxidase (HRP)-conjugated; Southern Biotechnology, Birmingham, AL) (1:1,000). The immune reaction was visualized with ECL or ECL-plus (Amersham Biosciences, Piscataway, NJ) according to the manufacturer's directions.
Immunohistochemistry
Frozen sections of normal human skin were acetone-fixed, chloroform-treated, rehydrated in PBS, blocked in 2% BSA/PBS, and exposed to serum overnight at 4 1C. Afterward, bound IgE was detected with anti-human IgE mAb B3102E8 (HRP-conjugated; Southern Biotechnology) (1:200) and visualized with AEC reagent (3-amino-9-ethylcarbazole; Sigma-Aldrich, St Louis, MO) according to the manufacturer's directions.
Immunofluorescence
Cytological analysis: culture slides. Primary KCs were grown on culture slides (Becton Dickinson) until 70% confluence, fixed with ice-cold acetone, blocked with 1% BSA/PBS þ 1% normal mouse serum (DakoCytomation, Glostrup, Denmark), and incubated with patient serum (1:5) for 1 hour on ice. After being washed with PBS buffer, bound IgE was detected with A488-labeled (mAb labeling kit; Invitrogen) mouse anti-human IgE-mAb B3102E8 (Southern Biotechnology). Slides were examined with a confocal www.jidonline.org 2237 S Altrichter et al. Cytological analysis: culture slides of living KCs. Primary KCs were grown on culture slides (Becton Dickinson) until 70% confluence, blocked with 1% BSA/PBS þ 1% normal goat serum (DakoCytomation), and incubated with patient serum (1:3) for 1 hour on ice. After being washed with PBS buffer, bound IgE was detected with mouse anti-human IgE-mAb B3102E8 (Southern Biotechnology) and goat anti-mouse IgG A488 (Invitrogen). Propidium iodide (final concentration, 1 mM; Invitrogen) was added to visualize dead cells. Consequently, cells were fixed and permeabilized (cell permeabilization kit; An der Grub, Kaumberg, Austria) according to the manufacturer's protocol and stained with rhodamine-phalloidin (Molecular Probes, Eugene, OR). Slides were examined with a Zeiss Axiophot fluorescent microscope and images were obtained from areas where no propidium iodide-positive cells were visible by light microscopy.
Statistics
Statistical analysis was performed using box-plot analysis and the Mann-Whitney U-test (SPSS 12; SPSS Inc., Chicago, IL). P-values o0.05 were considered statistically significant.
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